ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the first-in-class delta-like ligand 3/cluster of differentiation 3 bispecific T-cell engager approved globally for extensive-stage small cell lung cancer, tarlatamab still lacks comprehensive post-marketing safety data from real-world settings beyond clinical trials. This study employs the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to conduct a comprehensive evaluation of its safety profile, identifying potential risk signals and variations among subpopulations. A retrospective analysis was conducted using data from the FAERS prior to Q2 2025. Reports listing tarlatamab as the primary suspect drug were included. Signal detection employed quadruple disproportionality analysis (reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker). Adverse events (AEs) were standardized using the Medical Dictionary for Regulatory Activities v27.1. Subgroup analyses focused on sex, age, and clinical outcomes. Analysis of 676 tarlatamab-associated AE reports revealed extremely strong signals for core on-target toxicities: cytokine release syndrome (CRS) (ROR = 618.54) and immune effector cell-associated neurotoxicity syndrome (ICANS) (ROR = 1014.66). New safety signals included tumor lysis syndrome (TLS) (ROR = 48.15) and respiratory failure (ROR = 6.45), both of which exhibited significant disproportionality. Sex-based analysis identified significantly higher CRS risk in females versus males (ROR = 947.46 vs 400.82), while mortality reports were more prominent in males (ROR = 2.81). The overall onset time for all AEs exhibited an early failure pattern, with a median onset time of 3 days (interquartile range, 1-10). Clinical outcomes analysis indicated death events in 12.9% of cases and hospitalization requirements in 20.9%. Leveraging FAERS, this first comprehensive real-world characterization of tarlatamab safety confirms core immune-related toxicities (CRS, ICANS) and identifies new signals (TLS, respiratory failure), with sex- and age-associated risk differences. As spontaneous-report signals are inherently hypothesis-generating, causality requires validation in robust pharmacoepidemiologic studies; meanwhile, early detection and supportive care are essential to optimize the benefit-risk profile as use expands.
Indexed as
Identifiers
41609856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.